AI-enabled reinvention across the product lifecycle

AI that reaches the P&L,
not just the pilot stage.

MedTech Renaissance helps MedTech leaders find where AI and better operating decisions improve performance, then turns each opportunity into a funded plan with a named owner.

Most AI effort in MedTech never shows up in the financials.

Pilots in separate corners

Each function runs its own experiments, with no shared view of value or priority.

No line to the P&L

Savings are not tied to a financial line, and overlap between use cases is never netted out.

Regulation left out

FDA, MDR and software validation add time and cost that most business cases ignore.

The MedTech Value Architecture

Ten functions. Five outcomes.
One chain of value.

We assess where AI can change performance across the product lifecycle, and connect every use case to a measurable business outcome.

Product strategyR&DClinical evidenceRegulatory affairsQualitySourcingManufacturingSupply chainCommercial operationsService
Faster developmentMore profitable growthStronger marginsImproved cash flowBetter returns on capital
Example: QualityAI-assisted CAPA and complaint triage
Operating driverCost of poor quality, cycle time
Financial lineCOGS and opex
OutcomeStronger margins

Numbers a CFO can defend.

Risk-adjusted

Every use case is reduced by an overlap haircut and a probability of realization.

Built for regulation

Validation, FDA and MDR timing are modeled as delay and cost, not ignored.

Owned and gated

Each initiative has a named executive, a KPI and a stage gate before scale funding.

An illustrative base case

What the method can show for a mid-sized MedTech.

$39Mnet run-rate EBIT uplift
+261basis points of EBIT margin
$93M5-year after-tax NPV

Illustrative archetype of about $1.5B revenue. Every input is an untested hypothesis, not a benchmark. Your numbers come from your own baseline.

A 16-week path to a funded plan.

Weeks 1 to 4

Baseline and assess

Load financials, map use cases by function, interview function owners.

Weeks 5 to 10

Quantify and prioritize

Validate impact ranges, net out overlap, add regulatory timing, rank the portfolio.

Weeks 11 to 16

Plan and mobilize

Set owners, KPIs and stage gates, build the investment case, launch first-wave initiatives.

Want a smaller first step? A 2 to 3 week value snapshot runs the method on your baseline P&L and returns your top ten use cases.

Start with a 30-minute conversation.

Bring one executive sponsor and your latest P&L. We will show how the method would apply to your portfolio.

MedTech Renaissance by Therion Partners. Reimagining how MedTech innovates, operates, and creates value. All figures shown are illustrative.